Writing Committee MembersACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1-e167.
2.
The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
3.
BakerJG. The selectivity of β-adrenoreceptor antagonists at the human β1, β2 and β3 adrenoreceptors. Br J Pharmacol. 2005;144:317-322.
4.
MartiHPLopezAAPSchwartzmanP. Safety and tolerability of beta-blockers: importance of cardioselectivity. Curr Med Res Opin. 2024;40:55-62.
5.
DransfieldMTVoelkerHBhattSP, et al.Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381:2304-2314.
6.
DevereuxGCottonSNathM, et al.Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS randomized clinical trial. JAMA. 2024;332:462-470.
7.
NozawaTTaguchiMTaharaK, et al.Influence of CYP 2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005;46:713-720.
8.
BertilssonLLouYQDuYL, et al.Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992;51:388-397.
